Lung Clinical Trials

With multiple research labs at Cedars-Sinai, our leading lung specialists and research scientists work together to pioneer new imaging technologies, therapies and minimally invasive surgical techniques. As a patient with us, you'll have the potential to participate in groundbreaking pulmonary clinical trials.

Questions? See the Clinical Trial FAQs.


Click below to view clinical trials by areas:

Interstitial Lung Disease

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • ≥40 years old
  • Diagnosed with IPF within four years of screening
  • Diagnosis of IPF is supported by high resolution computed tomography and historical surgical lung biopsy

Summary:

The purpose of this study is to determine the effects of an investigational drug called CC-90001 on patients diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which scarring of the lungs occurs. Participants will be randomly assigned to receive CC-90001 or placebo (inactive substance). Researchers will assess the effect of CC-90001 on improving IPF, in addition to how well the body tolerates the drug. Another purpose of the study is to determine whether a biomarker test can show how IPF is affected by CC-90001 in a specific group of cells in the body. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • At least 40 years old
  • Women must be surgically sterile, postmenopausal or agree to use contraception; male subjects must agree to use one or more forms of birth control.
  • Diagnosis of IPF

Summary:

The purpose of this study is to evaluate the investigational use of a drug called BG00011 in patients with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. The study aims to determine the safety and effectiveness of the drug compared to placebo (inactive substance) in these patients. BG00011 is a laboratory-made antibody that is being developed to treat IPF. An antibody is a type of protein that is made by the body to help protect it from harmful substances. Participants will be randomly assigned to receive either BG00011 or placebo. Researchers also aim to learn whether a biomarker test will help determine the effects of BG00011 on the patient’s IPF. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.

Pulmonary Embolism

Condition:

Pulmonary embolism

Key Inclusion Criteria

  • 18-75 years old with body weight between 50-130 kg (110-286 lbs)
  • Admitted to the hospital with a clinical diagnosis of acute PE with an onset of symptoms in the five days prior to diagnosis categorized as low-risk, intermediate-risk or submassive PE and for whom catheter-based therapy is not planned

Summary:

This study focuses on individuals who have a blood clot in their lung(s) called a pulmonary embolism (PE). Normal standard of care for a blood clot is treatment with heparin followed by a blood thinner. The purpose of the study is to evaluate the safety of increasing doses of an investigational drug called DS-1040b when administered with standard-of-care treatment and to assess whether adding this drug to standard of care may help in the treatment of blood clots. Researchers aim to determine the best way to give DS-1040b and which dose of the drug is safe to use. Participants will be randomly assigned to receive either DS-1040b or placebo (inactive substance).

Pulmonary Vascular Disease

Condition:

Pulmonary hypertension

Key Inclusion Criteria

  • At least 18 years old
  • Surgical implantation of LVAD
  • Evidence of pulmonary hypertension on baseline right heart catheterization

Summary:

The purpose of this study is to evaluate the safety and effects of an investigational drug called macitentan in patients with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation. Pulmonary hypertension is a disorder of the blood vessels of the lungs, which can occur or worsen after implantation of an LVAD. Researchers will assess the effects of macitentan on the properties and function of the heart, as well as on blood pressure in the pulmonary arteries.

Condition:

Pulmonary hypertension

Key Inclusion Criteria

  • Patients newly treated with Opsumit defined as a new user of therapy, initiated less than or equal to 30 days prior to enrollment visit or at enrollment
  • Signed informed consent

Summary:

This observational study focuses on patients who are initiating therapy with a drug called Opsumit for the treatment of pulmonary arterial hypertension or another etiology (cause of disease). The purpose of the OPUS registry is to better understand the use of Opsumit in the clinical practice, including further characterization of the safety profile for the drug. Other goals include describing the demographic and clinical characteristics of patients treated with Opsumit. Opsumit is approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension.